Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMP Prima BioMed	$1.64 +0.6%	$1.80	$1.32 ▼ $2.72	$239.51M	1.76	193,592 shs	56,504 shs
OSMT Osmotica Pharmaceuticals		$1.16	$0.98 ▼ $4.95	$69.47M	2.34	396,682 shs	296,500 shs
PVLA Palvella Therapeutics	$22.08 +7.1%	$23.54	$6.20 ▼ $29.27	$244.21M	-0.1	136,637 shs	1.14 million shs
TERN Terns Pharmaceuticals	$3.83 -4.3%	$3.35	$1.87 ▼ $11.40	$334.51M	-0.18	1.47 million shs	1.46 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMP Prima BioMed	0.00%	+2.50%	-14.14%	-6.82%	-18.41%
OSMT Osmotica Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PVLA Palvella Therapeutics	0.00%	+0.14%	-9.14%	-21.11%	+2,207,999,900.00%
TERN Terns Pharmaceuticals	0.00%	-1.79%	+22.76%	+38.77%	-43.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMMP Prima BioMed	1.4241 of 5 stars	3.5	1.0	0.0	0.0	2.7	0.0	0.0
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	3.2702 of 5 stars	3.6	0.0	0.0	0.0	2.5	4.2	0.6
TERN Terns Pharmaceuticals	4.2091 of 5 stars	3.3	1.0	0.0	4.1	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMP Prima BioMed	3.00	Buy	$7.00	326.83% Upside
OSMT Osmotica Pharmaceuticals	0.00	N/A	N/A	N/A
PVLA Palvella Therapeutics	3.13	Buy	$46.29	109.63% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	307.96% Upside

Current Analyst Ratings Breakdown

Latest OSMT, TERN, PVLA, and IMMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/21/2025	TERN Terns Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/1/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMP Prima BioMed	$5.14M	46.60	N/A	N/A	$1.05 per share	1.56
OSMT Osmotica Pharmaceuticals	$177.88M	0.00	N/A	1.00	$1.50 per share	0.00
PVLA Palvella Therapeutics	$42.81M	5.70	N/A	N/A	$5.58 per share	3.96
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
OSMT Osmotica Pharmaceuticals	-$79.59M	-$1.59	N/A	N/A	N/A	-138.76%	-81.23%	-20.97%	N/A
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)
TERN Terns Pharmaceuticals	-$88.85M	-$1.09	N/A	N/A	N/A	N/A	-28.81%	-27.55%	8/4/2025 (Estimated)

Latest OSMT, TERN, PVLA, and IMMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMP Prima BioMed	N/A	18.86	N/A
OSMT Osmotica Pharmaceuticals	N/A	0.43	0.42
PVLA Palvella Therapeutics	N/A	8.84	8.84
TERN Terns Pharmaceuticals	N/A	30.89	30.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMP Prima BioMed	2.32%
OSMT Osmotica Pharmaceuticals	46.18%
PVLA Palvella Therapeutics	40.11%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
IMMP Prima BioMed	3.07%
OSMT Osmotica Pharmaceuticals	5.22%
PVLA Palvella Therapeutics	20.50%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
OSMT Osmotica Pharmaceuticals	302	62.59 million	59.32 million	Not Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
TERN Terns Pharmaceuticals	40	87.34 million	86.03 million	Not Optionable

OSMT, TERN, PVLA, and IMMP Headlines

Recent News About These Companies

Terns pharmaceuticals CEO Burroughs buys $90k in shares

June 27 at 5:01 PM | investing.com

Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

June 26, 2025 | fiercebiotech.comF

Insider Buying: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Buys 23,314 Shares of Stock

June 25, 2025 | marketbeat.com

Terns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - Nasdaq

June 24, 2025 | nasdaq.com

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - Morningstar

June 24, 2025 | morningstar.comM

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

June 23, 2025 | medpagetoday.comM

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

June 23, 2025 | globenewswire.com

Population-Level Weight Loss Seen With Primary Care Protocol

June 21, 2025 | medscape.comM

SG Americas Securities LLC Purchases 380,489 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

June 18, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys $19,750.00 in Stock

June 17, 2025 | insidertrades.com

Insider Buying: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys 5,000 Shares of Stock

June 16, 2025 | marketbeat.com

Andrew Gengos Buys 10,000 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

June 16, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

June 14, 2025 | marketbeat.com

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsight

June 13, 2025 | theglobeandmail.com

3 Penny Stocks Wall Street Sees With 243% Upside

June 11, 2025 | 247wallst.com

Bank of America Corp DE Purchases 138,661 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

June 7, 2025 | marketbeat.com

Voloridge Investment Management LLC Sells 98,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 31, 2025 | marketbeat.com

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 29, 2025 | globenewswire.com

Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential

May 27, 2025 | investing.com

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 14, 2025 | globenewswire.com

Why Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 11.67%

May 10, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
Top 3 Silver Picks to Watch as Bull Market Gains Steam
By Chris Markoch | June 18, 2025
View Top 3 Silver Picks to Watch as Bull Market Gains Steam
These 3 Stocks Are Buying Back Billions in Shares
By Leo Miller | June 3, 2025
View These 3 Stocks Are Buying Back Billions in Shares
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership

OSMT, TERN, PVLA, and IMMP Company Descriptions

Prima BioMed NASDAQ:IMMP

$1.64 +0.01 (+0.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.62 -0.02 (-1.52%)

As of 04:05 AM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Osmotica Pharmaceuticals NASDAQ:OSMT

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Palvella Therapeutics NASDAQ:PVLA

$22.08 +1.46 (+7.08%)

As of 06/27/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Terns Pharmaceuticals NASDAQ:TERN

$3.83 -0.17 (-4.25%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.38 +0.55 (+14.36%)

As of 04:00 AM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time